United States · Platforms & data · MarketBeat

Taysha Gene Therapies Q3 Earnings Call Highlights

Published by MarketBeat · United States 51 min ago

Image from MarketBeat Media, LLC. · MarketBeat

Detailed summary

Taysha Gene Therapies (NASDAQ:TSHA) expects to report pivotal trial data for its experimental Rett syndrome gene therapy TSHA-102 and provide feedback from U.S. regulators on a potential filing pathway in the first half of 2027, executives said on the company’s third-quarter earnings call. The comp

Read the full article on MarketBeat Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.marketbeat.com)

Also worth reading

Seeking Alpha

Peraso appoints Kevin Liu as interim CFO

MarketWatch

The S&P 500 is shrugging off Nvidia’s selloff this week. Here’s what’s keeping the rest of the market afloat.

CNBC

In a policy switch, the Fed says its October 2027 meeting will not see a vote on interest rates

Benzinga

Toncoin (TON) Price Prediction 2025, 2026, 2027-2030

Stocktwits

This Analyst Sees Huang's Resignation As Nvidia CEO As A 'One-Time Clearing Event' For Stock Market

Yahoo Finance